Co-administration of rivaroxaban with strong inhibitors of combined CYP3A4 and P-glycoprotein is contraindicated (increased plasma concentrations of rivaroxaban). Examples: synthetic azole antimycotics, such as ketoconazole, fluconazole, itraconazole, voriconazole, or posaconazole, if used systemically; HIV-protease inhibitors, such as ritonavir; clarithromycin, erythromycin.
Co-administration of rivaroxaban with strong inducers of CYP3A4 is contraindicated (decreased plasma concentrations of rivaroxaban). Examples: rifampicin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St John’s wort.
For participants who develop a need for any of these medications, the study medication must be temporarily discontinued. The study medication can be restarted once these medications are stopped or no longer required.
